Outcome and Prognostic Factors of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia
Acta Haematologica · 2024
DOI: 10.1159/000536396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Guan-Hua Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation, Core Binding Factor Alpha 2 Subunit. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Introduction
The role of haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) in pediatric patients with relapsed or refractory (R/R) ETV6/RUNX1-positive acute lymphoblastic leukemia (ALL) is unclear. This study aimed to identify prognostic factors and explore the role of haplo-HSCT in the treatment of ETV6/RUNX1-positive ALL.
Methods
We analyzed the clinical characteristics and treatment outcomes of 20 pediatric patients who were diagnosed with ETV6/RUNX1-positive ALL and received chemotherapy/chimeric antigen receptor T-cell bridged to haplo-HSCT between 2016 and 2021 at our institution.
Results
With a median follow-up time of 47 months, the 3-year cumulative incidence of relapse, disease-free survival, and overall survival were 35.9% (95% confidence interval (CI): 15.3–57.1%), 59.1% (95% CI: 37.2–81.0%), and 75.0% (95% CI: 56.0–94.0%), respectively. Multivariate analysis revealed that pre-HSCT measurable residual disease (MRD) positivity (hazard ratio, 13.275; 95% CI: 2.406–73.243; p = 0.003) had a significant negative impact on relapse. A total of 7 patients experienced positive ETV6/RUNX1 gene expression at a median of 7.2 months after haplo-HSCT, and 5 of them experienced relapse at a median time of 12.1 months after haplo-HSCT. ROC curve analysis was performed to analyze the significance of pre-HSCT and post-HSCT ETV6/RUNX1 transcripts for predicting relapse; the AUC were 0.798 (95% CI: 0.567–1.0, p = 0.035) and 0.875 (95% CI: 0.690–1.0, p = 0.008), respectively. The optimal cut-off points to predict an inevitable relapse were 0.011% and 0.0019%, respectively.
Conclusion
Patients with R/R ETV6/RUNX1-positive ALL may benefit from haplo-HSCT. Deeply eliminating pre-HSCT MRD and preemptive treatment for post-HSCT MRD may be crucial to further improving the prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsingh…
Zitieren
APA
Hu, G. H., Zhang, X. H., Liu, K. Y., Xu, L. P., Wang, Y., Cheng, Y. F., & Huang, X. J. (2024). Outcome and Prognostic Factors of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia. Acta Haematologica. https://doi.org/10.1159/000536396
Vancouver
Hu GH, Zhang XH, Liu KY, Xu LP, Wang Y, Cheng YF, et al. Outcome and Prognostic Factors of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia. Acta Haematologica. 2024. doi:10.1159/000536396
BibTeX
@article{Hu2024,
author = {Hu, Guan-Hua and Zhang, Xiao-Hui and Liu, Kai-Yan and Xu, Lan-Ping and Wang, Yu and Cheng, Yi-Fei and Huang, Xiao-Jun},
title = {Outcome and Prognostic Factors of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000536396}
}
EUVIMED